8,217 Shares in Revolution Medicines, Inc. $RVMD Purchased by Lido Advisors LLC

Lido Advisors LLC purchased a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 8,217 shares of the company’s stock, valued at approximately $1,687,000.

Several other large investors have also recently made changes to their positions in RVMD. AlphaCore Capital LLC purchased a new position in Revolution Medicines in the 3rd quarter valued at $361,000. Fulcrum Asset Management LLP acquired a new stake in Revolution Medicines during the 3rd quarter worth $197,000. Allspring Global Investments Holdings LLC boosted its stake in Revolution Medicines by 1,258.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 29,442 shares of the company’s stock worth $6,062,000 after purchasing an additional 27,275 shares during the last quarter. Brighton Jones LLC grew its holdings in shares of Revolution Medicines by 2.9% during the third quarter. Brighton Jones LLC now owns 3,565 shares of the company’s stock worth $732,000 after buying an additional 99 shares in the last quarter. Finally, Ethic Inc. grew its holdings in shares of Revolution Medicines by 32.8% during the third quarter. Ethic Inc. now owns 3,571 shares of the company’s stock worth $733,000 after buying an additional 881 shares in the last quarter. 94.34% of the stock is currently owned by hedge funds and other institutional investors.

Revolution Medicines Stock Performance

Shares of Revolution Medicines stock opened at $172.29 on Monday. Revolution Medicines, Inc. has a one year low of $63.50 and a one year high of $224.31. The company has a market cap of $37.26 billion, a price-to-earnings ratio of -18.91 and a beta of 1.44. The company has a debt-to-equity ratio of 0.44, a quick ratio of 8.34 and a current ratio of 8.36. The business’s 50 day moving average price is $194.46 and its 200 day moving average price is $159.42.

Revolution Medicines (NASDAQ:RVMD – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($1.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.35) by $0.45. The company had revenue of $197.56 million for the quarter, compared to analyst estimates of $25.58 million. During the same period last year, the firm posted ($1.61) EPS. On average, research analysts predict that Revolution Medicines, Inc. will post -7.41 EPS for the current year.

Insiders Place Their Bets

In other Revolution Medicines news, COO Margaret Horn sold 4,967 shares of the firm’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $199.24, for a total value of $989,625.08. Following the completion of the sale, the chief operating officer directly owned 149,680 shares of the company’s stock, valued at $29,822,243.20. This trade represents a 3.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jack Anders sold 35,750 shares of Revolution Medicines stock in a transaction on Wednesday, November 11th. The stock was sold at an average price of $188.10, for a total value of $6,724,575.00. Following the transaction, the chief financial officer owned 119,216 shares in the company, valued at approximately $22,424,529.60. This represents a 23.07% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 326,741 shares of company stock worth $66,147,340. 7.60% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Evercore reiterated an “outperform” rating and issued a $320.00 target price on shares of Revolution Medicines in a research report on Thursday, August 27th. Piper Sandler raised their price target on shares of Revolution Medicines from $210.00 to $222.00 and gave the stock an “overweight” rating in a research note on Thursday, November 5th. TD Cowen boosted their price target on shares of Revolution Medicines from $250.00 to $270.00 and gave the stock a “buy” rating in a research report on Thursday, November 5th. UBS Group upped their price objective on shares of Revolution Medicines from $220.00 to $265.00 and gave the company a “buy” rating in a research note on Friday, August 28th. Finally, Bank of America dropped their price objective on shares of Revolution Medicines from $265.00 to $264.00 and set a “buy” rating for the company in a research note on Friday, October 9th. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $262.75.

Check Out Our Latest Stock Report on Revolution Medicines

About Revolution Medicines

(Free Report)

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers. The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.

Read More

Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report).

Institutional Ownership by Quarter for Revolution Medicines (NASDAQ:RVMD)

Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.